Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

RATIONALE: There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not to treat patients with preserved lung volume. OBJECTIVE: To investigate whether patients with IPF and preserved lung volume receive the same benefit from nint...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolb, Martin, Richeldi, Luca, Behr, Jürgen, Maher, Toby M, Tang, Wenbo, Stowasser, Susanne, Hallmann, Christoph, du Bois, Roland M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520269/
https://www.ncbi.nlm.nih.gov/pubmed/27672117
http://dx.doi.org/10.1136/thoraxjnl-2016-208710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520269/
https://www.ncbi.nlm.nih.gov/pubmed/27672117
http://dx.doi.org/10.1136/thoraxjnl-2016-208710

Ejemplares similares